Efficacy and safety of twice-daily aclidinium bromide in COPD patients: The ATTAIN study

European Respiratory Journal

Volumn 40, Issue 4, 2012, Pages 830-836

  Jones, Paul W ^a   Singh, Dave ^b   Bateman, Eric D ^c   Agusti, Alvar ^d,e   Lamarca, Rosa ^f   De Miquel, Gonzalo ^f   Segarra, Rosa ^f   Caractae, Cynthia ^g   Gi, Esther Garcia ^f  

^a ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

^b UNIVERSITY OF MANCHESTER   (United Kingdom)

^c UNIVERSITY OF CAPE TOWN   (South Africa)

^d UNIVERSITY OF BARCELONA   (Spain)

^e INSTITUTO DE SALUD CARLOS III   (Spain)

^f Almirall SA ^*  (Spain)

^g FOREST RESEARCH INSTITUTE   (United States)

Author keywords

Anticholinergic; Bronchodilation; Dyspnoea; Exacerbations; Health status; Long acting muscarinic antagonist

Indexed keywords

ACLIDINIUM BROMIDE; GENUAIR; PLACEBO; UNCLASSIFIED DRUG;

ADULT; ARTHRALGIA; ARTICLE; BACKACHE; BRONCHITIS; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONTROLLED STUDY; COUGHING; DIARRHEA; DISEASE EXACERBATION; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DYSPEPSIA; DYSPNEA; FEMALE; FORCED EXPIRATORY VOLUME; HEALTH STATUS; HUMAN; HYPERTENSION; INFLUENZA; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; RHINITIS; RHINOPHARYNGITIS; SCORING SYSTEM; TOOTH PAIN; TREATMENT DURATION; TREATMENT RESPONSE; URINARY TRACT INFECTION; XEROSTOMIA;

ADMINISTRATION, INHALATION; AGED; BRONCHODILATOR AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DYSPNEA; FEMALE; FORCED EXPIRATORY VOLUME; HEALTH STATUS; HUMANS; MALE; METERED DOSE INHALERS; MIDDLE AGED; MUSCARINIC ANTAGONISTS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; TROPANES;

EID: 84867119092     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/09031936.00225511     Document Type: Article

References (18)

1. Mannino DM, Buist AS. Global burden of COPD: risk factors, prevalence, and future trends. Lancet 2007; 370: 765-773. (Pubitemid 47321908)
2. Global Initiative for Chronic Obstructive Lung Disease. Global Strategy for Diagnosis, Management, and Prevention of COPD. www.goldcopd.com. Date last updated: 2010. Date last accessed: August 26, 2011.
3. Vestbo J, Edwards LD, Scanlon PD, et al. Changes in forced expiratory volume in 1 second over time in COPD. N Engl J Med 2011; 365: 1184-1192.
4. Jones PW, Rennard SI, Agusti A, et al. Efficacy and safety of oncedaily aclidinium in chronic obstructive pulmonary disease. Respir Res 2011; 12: 55.
5. Cazzola M, MacNee W, Martinez FJ, et al. Outcomes for COPD pharmacological trials: from lung function to biomarkers. Eur Respir J 2008; 31: 416-469.
6. Donohue JF. Minimal clinically important differences in COPD lung function. COPD 2005; 2: 111-124. (Pubitemid 40776231)
7. Fuhr R, Magnussen H, Sarem K, et al. Efficacy of aclidinium bromide 400 mg twice daily compared with placebo and tiotropium in patients with moderate to severe COPD. Chest 2012; 141: 745-752.
8. Kerwin EM, D'Urzo AD, Gelb AF, et al. Efficacy and safety of a 12-week treatment with twice-daily aclidinium bromide in COPD patients (ACCORD COPD I). COPD 2012; 9: 90-101.
9. Miller MR, Hankinson J, Brusasco V, et al. Standardisation of spirometry. Eur Respir J 2005; 26: 319-338. (Pubitemid 41079078)
10. Jones PW. St George's Respiratory Questionnaire: MCID. COPD 2005; 2: 75-79.
11. Mahler DA, Witek TJ Jr. The MCID of the transition dyspnea index is a total score of one unit. COPD 2005; 2: 99-103. (Pubitemid 40776229)
12. Westwood M, Bourbeau J, Jones PW, et al. Relationship between FEV1 change and patient-reported outcomes in randomised trials of inhaled bronchodilators for stable COPD: a systematic review. Respir Res 2011; 12: 40.
13. Jansat JM, Lamarca R, Garcia Gil E, et al. Safety and pharmacokinetics of single doses of aclidinium bromide, a novel long-acting, inhaled antimuscarinic, in healthy subjects. Int J Clin Pharmacol Ther 2009; 47: 460-468.
14. Sentellas S, Ramos I, Alberti J, et al. Aclidinium bromide, a new, long-acting, inhaled muscarinic antagonist: in vitro plasma inactivation and pharmacological activity of its main metabolites. Eur J Pharm Sci 2010; 39: 283-290.
15. Brusasco V, Hodder R, Miravitlles M, et al. Health outcomes following treatment for six months with once daily tiotropium compared with twice daily salmeterol in patients with COPD. Thorax 2003; 58: 399-404. (Pubitemid 36560942)
16. Casaburi R, Mahler DA, Jones PW, et al. A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease. Eur Respir J 2002; 19: 217-224. (Pubitemid 34162820)
17. Donohue JF, van Noord JA, Bateman ED, et al. A 6-month, placebo-controlled study comparing lung function and health status changes in COPD patients treated with tiotropium or salmeterol. Chest 2002; 122: 47-55. (Pubitemid 34754142)
18. Vincken W, van Noord JA, Greefhorst AP, et al. Improved health outcomes in patients with COPD during 1 yr's treatment with tiotropium. Eur Respir J 2002; 19: 209-216. (Pubitemid 34162819)